Phase 3 Stroke Trial, Recruiting NCT06296082 Sponsor: Universiteit Antwerpen Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06296082
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old
  • People who have muscle stiffness in the ankle and foot (specifically the muscles that point the foot downward) following a stroke, rated as mild to moderate on a standard scale
  • People who have had their first stroke only
  • People whose stroke occurred within the last 12 months
  • People who have not previously received Botulinum Toxin A injections or dry needling treatment for muscle stiffness
  • People whose ankle can be moved passively through at least approximately 20 degrees of motion when the knee is slightly bent
  • People who are able to walk on their own, with or without a walking aid such as a cane or walker

Who may not be able to join:

  • People with other health conditions that could make it difficult to interpret the trial results
  • People who have medical reasons why Botulinum Toxin A injections or dry needling would not be safe for them
  • People whose medication for muscle stiffness has had its dose changed during the trial period or within the 3 months before joining
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pablo Herrero Gallego, PhD, Universidad de Zaragoza

Phone: +34646168248

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Universiteit Antwerpen
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
30 December 2026

Where this trial is recruiting

🇧🇪 Belgium 🇨🇦 Canada 🇪🇸 Spain

Primary endpoints

Tonic Stretch Reflex Threshold (TSRT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov